DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
van der Heijde D, Baraliakos X, Gensler LS. et al.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Lancet 2018;
392: 2378-2387. doi: 10.1016/S0140-6736(18)32463-2
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.